EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Neoadjuvant chemoimmunotherapy was associated with better short‐term survival of patients with locally advanced esophageal squamous cell carcinoma compared to neoadjuvant chemoradiotherapy

Xiaofeng Duan iD, Fangdong Zhao, Xiaobin Shang, Jie Yue, Chuangui Chen, Zhao Ma, Zuoyu Chen, Chen Zhang, Qingsong Pang, Wencheng Zhang, Abbas E Abbas, Hongjing Jiang

Cancer Medicine · 2024-08 · 13 (15)

DOI: 10.1002/cam4.70113 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Medicine, online erschienen am 13.08.2024. Verfasst von Xiaofeng Duan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Minimally Invasive Esophageal Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for …. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophagectomy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Construction Project of Precision Treatment of Oncology Surgery in the Tianjin Medical University Cancer Hospital, The "14th Five-Year" Peak Discipline Support Program of the Tianjin Medical University Cancer Hospital, Important Specific Projects of Public Health of the Tianjin Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The chemotherapy and immunotherapy combination is currently the primary strategy to treat metastatic esophageal squamous cell carcinoma (ESCC). Neoadjuvant chemoimmunotherapy (NCIT) is being intensively investigated for treating locally advanced ESCC.

Objective

We compared the efficacy and safety of NCIT and neoadjuvant chemoradiotherapy (NCRT) to treat locally advanced ESCC.

Methods

We included 214 locally advanced ESCC patients who were administered neoadjuvant therapy from May 2014 to April 2022. The patients were grouped according to two neoadjuvant protocols (NCIT and NCRT) routinely used at our institution. Perioperative findings, pathological results, and survival data were compared between the two groups by conducting unmatched and 1:1 propensity score matching (PSM) analyses.

Results

Following 1:1 PSM analysis of the confounders, 66 patients were allocated to each of the two groups. Time span between neoadjuvant therapy completion and esophagectomy was significantly longer after NCRT than that after NCIT (47.1 ± 13.2 days vs. 34.7 ± 8.8 days; p < 0.001). The NCIT group exhibited significantly greater number of harvested lymph nodes than the NCRT group (33.6 ± 12.7 vs. 21.7 ± 10.2; p < 0.001). The pathological complete response and major pathological response rates were similar between the two groups [NCIT group: 25.8% (17/66) and 62.1% (41/66), respectively; NCRT group: 27.3% (18/66) and 56.1% (37/66), respectively ( p > 0.05)]. The overall incidence of pneumonia, anastomotic leakage, or postoperative complications did not differ significantly between the two groups. The 2‐year cumulative overall survival rates and the 2‐year disease‐free survival rates of the NCIT and NCRT groups were 80.2% and 62.2%, respectively ( p = 0.029) and 70.0% and 50.8%, respectively ( p = 0.023).

Conclusion

In locally advanced ESCC patients, short‐term survival after NCIT is superior to that after NCRT, with similar perioperative and pathological outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsEsophagectomyHumansMaleFemaleMiddle AgedAgedChemoradiotherapyAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyRetrospective StudiesTreatment OutcomePropensity Score

Stichwörter der Autor:innen

chemoradiotherapyesophageal squamous cell carcinomaimmunotherapyneoadjuvant therapy

Autor:innen und Institutionen

  • Department of Minimally Invasive Esophageal Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory…
  • Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Department of Thoracic Oncology, Lifespan Health System, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

ORCID-Profile: Xiaofeng Duan

Förderung

  • Construction Project of Precision Treatment of Oncology Surgery in the Tianjin Medical University Cancer Hospital
  • The "14th Five-Year" Peak Discipline Support Program of the Tianjin Medical University Cancer Hospital
  • Important Specific Projects of Public Health of the Tianjin Science and Technology Bureau

Zitieren

APA

Duan, X., Zhao, F., Shang, X., Yue, J., Chen, C., Ma, Z., Chen, Z., Zhang, C., Pang, Q., Zhang, W., Abbas, A. E., & Jiang, H. (2024). Neoadjuvant chemoimmunotherapy was associated with better short‐term survival of patients with locally advanced esophageal squamous cell carcinoma compared to neoadjuvant chemoradiotherapy. Cancer Medicine, 13(15). https://doi.org/10.1002/cam4.70113

Vancouver

Duan X, Zhao F, Shang X, Yue J, Chen C, Ma Z, et al. Neoadjuvant chemoimmunotherapy was associated with better short‐term survival of patients with locally advanced esophageal squamous cell carcinoma compared to neoadjuvant chemoradiotherapy. Cancer Medicine. 2024;13(15). doi:10.1002/cam4.70113

BibTeX
@article{Duan2024,
  author = {Duan, Xiaofeng and Zhao, Fangdong and Shang, Xiaobin and Yue, Jie and Chen, Chuangui and Ma, Zhao and Chen, Zuoyu and Zhang, Chen and Pang, Qingsong and Zhang, Wencheng and Abbas, Abbas E and Jiang, Hongjing},
  title = {Neoadjuvant chemoimmunotherapy was associated with better short‐term survival of patients with locally advanced esophageal squamous cell carcinoma compared to neoadjuvant chemoradiotherapy},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {15},
  doi = {10.1002/cam4.70113}
}
Kostenlos starten →